Q2 Earnings Estimate for MMSI Issued By Barrington Research

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Investment analysts at Barrington Research lowered their Q2 2025 EPS estimates for shares of Merit Medical Systems in a research note issued on Friday, April 25th. Barrington Research analyst M. Petusky now anticipates that the medical instruments supplier will post earnings per share of $0.88 for the quarter, down from their previous forecast of $1.03. Barrington Research has a “Outperform” rating and a $103.00 price objective on the stock. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.37 per share. Barrington Research also issued estimates for Merit Medical Systems’ Q3 2025 earnings at $0.80 EPS, Q4 2025 earnings at $0.80 EPS, Q1 2026 earnings at $0.81 EPS, Q2 2026 earnings at $1.05 EPS, Q3 2026 earnings at $0.91 EPS, Q4 2026 earnings at $0.94 EPS and FY2027 earnings at $4.05 EPS.

Several other equities analysts have also commented on the company. Wells Fargo & Company set a $106.00 target price on Merit Medical Systems and gave the company an “overweight” rating in a report on Friday. Canaccord Genuity Group reduced their price target on shares of Merit Medical Systems from $127.00 to $108.00 and set a “buy” rating for the company in a report on Friday, April 25th. Robert W. Baird cut their price objective on shares of Merit Medical Systems from $111.00 to $110.00 and set an “outperform” rating on the stock in a research report on Friday, April 25th. Needham & Company LLC dropped their price target on shares of Merit Medical Systems from $116.00 to $100.00 and set a “buy” rating on the stock in a research note on Friday, April 25th. Finally, Raymond James reduced their price objective on Merit Medical Systems from $116.00 to $108.00 and set an “outperform” rating for the company in a research report on Friday, April 25th. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Merit Medical Systems currently has a consensus rating of “Moderate Buy” and an average price target of $107.78.

Merit Medical Systems Trading Down 0.7 %

Merit Medical Systems stock opened at $94.76 on Monday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.82 and a current ratio of 5.36. Merit Medical Systems has a 1 year low of $73.67 and a 1 year high of $111.45. The firm’s 50-day moving average is $98.16 and its 200-day moving average is $100.56. The company has a market cap of $5.60 billion, a P/E ratio of 46.45, a PEG ratio of 2.34 and a beta of 0.85.

Merit Medical Systems (NASDAQ:MMSI) last released its earnings results on Thursday, April 24th. The medical instruments supplier reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.11. Merit Medical Systems had a return on equity of 15.61% and a net margin of 9.05%. The company had revenue of $355.35 million for the quarter, compared to the consensus estimate of $352.57 million. During the same quarter last year, the business posted $0.77 EPS. Merit Medical Systems’s quarterly revenue was up 9.8% compared to the same quarter last year.

Institutional Trading of Merit Medical Systems

Several institutional investors have recently made changes to their positions in the stock. Louisiana State Employees Retirement System increased its stake in shares of Merit Medical Systems by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 28,200 shares of the medical instruments supplier’s stock worth $2,728,000 after acquiring an additional 100 shares during the last quarter. Avantax Advisory Services Inc. grew its stake in shares of Merit Medical Systems by 4.6% in the 4th quarter. Avantax Advisory Services Inc. now owns 2,347 shares of the medical instruments supplier’s stock valued at $227,000 after buying an additional 103 shares in the last quarter. Tidal Investments LLC increased its holdings in Merit Medical Systems by 1.0% in the third quarter. Tidal Investments LLC now owns 10,398 shares of the medical instruments supplier’s stock worth $1,028,000 after buying an additional 104 shares during the last quarter. Arizona State Retirement System raised its position in Merit Medical Systems by 0.8% during the fourth quarter. Arizona State Retirement System now owns 16,869 shares of the medical instruments supplier’s stock valued at $1,632,000 after acquiring an additional 137 shares in the last quarter. Finally, Summit Investment Advisors Inc. lifted its stake in Merit Medical Systems by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 5,987 shares of the medical instruments supplier’s stock valued at $579,000 after acquiring an additional 190 shares during the last quarter. 99.66% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CFO Raul Jr. Parra sold 12,451 shares of the company’s stock in a transaction on Friday, February 28th. The stock was sold at an average price of $98.81, for a total transaction of $1,230,283.31. Following the transaction, the chief financial officer now directly owns 24,201 shares of the company’s stock, valued at approximately $2,391,300.81. The trade was a 33.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Brian G. Lloyd sold 25,000 shares of the firm’s stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $99.50, for a total value of $2,487,500.00. Following the sale, the insider now owns 38,993 shares of the company’s stock, valued at $3,879,803.50. The trade was a 39.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 109,132 shares of company stock valued at $11,139,521 over the last three months. Insiders own 3.70% of the company’s stock.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.